Title

DNA Sequencing versus Standard Prenatal Aneuploidy Screening

Publication Date

2014

Journal Title

N Engl J Med

Abstract

BackgroundIn high-risk pregnant women, noninvasive prenatal testing with the use of massively parallel sequencing of maternal plasma cell-free DNA (cfDNA testing) accurately detects fetal autosomal aneuploidy. Its performance in low-risk women is unclear. MethodsAt 21 centers in the United States, we collected blood samples from women with singleton pregnancies who were undergoing standard aneuploidy screening (serum biochemical assays with or without nuchal translucency measurement). We performed massively parallel sequencing in a blinded fashion to determine the chromosome dosage for each sample. The primary end point was a comparison of the false positive rates of detection of fetal trisomies 21 and 18 with the use of standard screening and cfDNA testing. Birth outcomes or karyotypes were the reference standard. ResultsThe primary series included 1914 women (mean age, 29.6 years) with an eligible sample, a singleton fetus without aneuploidy, results from cfDNA testing, and a risk classification based on standard screening. For trisomies 21 and 18, the false positive rates with cfDNA testing were significantly lower than those with standard screening (0.3% vs. 3.6% for trisomy 21, P

Volume Number

370

Issue Number

9

Pages

799-808

Document Type

Article

Status

Faculty

Facility

School of Medicine

Primary Department

Obstetrics and Gynecology

PMID

24571752

DOI

10.1056/NEJMoa1311037

For the public and Northwell Health campuses

Share

COinS